Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma
Shaofang Wu, Xiaolong Li, Feng Gao, et al.
Neuro-Oncology (2021) Vol. 23, Iss. 6, pp. 920-931
Open Access | Times Cited: 93

Showing 26-50 of 93 citing articles:

Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistance
Junhu Zhou, Fei Tong, Jixing Zhao, et al.
Cancer Biology and Medicine (2023) Vol. 20, Iss. 5, pp. 385-400
Open Access | Times Cited: 10
Epigenetic regulation of temozolomide resistance in human cancers with an emphasis on brain tumors: Function of non-coding RNAs
Aryan Rezaee, Pooya M. Tehrany, Farimah Jafari Tirabadi, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 165, pp. 115187-115187
Open Access | Times Cited: 10
Comparative analysis of pyrosequencing and next-generation sequencing for assessing MGMT methylation in glioma patients
Huanming Shen, Zhi Zhou, Xiaoni Zhang, et al.
Journal of Neuro-Oncology (2025)
Closed Access
A Hybrid-Targeting Nanoparticle for Penetrable Delivery of Temozolomide to Enhance Glioblastoma Therapy
Guanru Wang, Hao Guo, Mengxin Wei, et al.
Nano Letters (2025)
Closed Access
Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review
Jiaqi Xiong, Ranya Barayan, Alexander V. Louie, et al.
Seminars in Cancer Biology (2022) Vol. 86, pp. 521-542
Open Access | Times Cited: 16
Drug Repurposing, a Fast-Track Approach to Develop Effective Treatments for Glioblastoma
Ioannis Ntafoulis, Stijn L.W. Koolen, Sieger Leenstra, et al.
Cancers (2022) Vol. 14, Iss. 15, pp. 3705-3705
Open Access | Times Cited: 16
Multicellular Complex Tumor Spheroid Response to DNA Repair Inhibitors in Combination with DNA-damaging Drugs
Thomas S. Dexheimer, Nathan P. Coussens, Thomas Silvers, et al.
Cancer Research Communications (2023) Vol. 3, Iss. 8, pp. 1648-1661
Open Access | Times Cited: 8
EPIC-1042 as a potent PTRF/Cavin1–caveolin-1 interaction inhibitor to induce PARP1 autophagic degradation and suppress temozolomide efflux for glioblastoma
Biao Hong, Eryan Yang, Dongyuan Su, et al.
Neuro-Oncology (2023) Vol. 26, Iss. 1, pp. 100-114
Open Access | Times Cited: 8
Temozolomide and the PARP Inhibitor Niraparib Enhance Expression of Natural Killer Group 2D Ligand ULBP1 and Gamma-Delta T Cell Cytotoxicity in Glioblastoma
Amber B. Jones, Kaysaw Tuy, Cyntanna C. Hawkins, et al.
Cancers (2024) Vol. 16, Iss. 16, pp. 2852-2852
Open Access | Times Cited: 3
Development of Next-Generation Poly(ADP-Ribose) Polymerase 1–Selective Inhibitors
Natalie Ngoi, Elisabetta Leo, Mark J. O’Connor, et al.
The Cancer Journal (2021) Vol. 27, Iss. 6, pp. 521-528
Closed Access | Times Cited: 18
The Emerging Roles and Therapeutic Implications of Epigenetic Modifications in Ovarian Cancer
Yu Wang, Zhao Huang, Bowen Li, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 13
HOXD‐AS2‐STAT3 feedback loop attenuates sensitivity to temozolomide in glioblastoma
Zuo‐Xin Zhang, Ren Peng, Yong‐Yong Cao, et al.
CNS Neuroscience & Therapeutics (2023) Vol. 29, Iss. 11, pp. 3430-3445
Open Access | Times Cited: 7
Advances in screening, synthesis, modification, and biomedical applications of peptides and peptide aptamers
Yijie Liu, Xiaoling Lü, Meilun Chen, et al.
BioFactors (2023) Vol. 50, Iss. 1, pp. 33-57
Closed Access | Times Cited: 7
PARP1-MGMT complex underpins pathway crosstalk in O6-methylguanine repair
Jodie Cropper, Dauren Alimbetov, Kevin T. G. Brown, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 12
Transformed astrocytes confer temozolomide resistance on glioblastoma via delivering ALKBH7 to enhance APNG expression after educating by glioblastoma stem cells‐derived exosomes
Xinglei Liu, Liang Liu, Anyi Wu, et al.
CNS Neuroscience & Therapeutics (2024) Vol. 30, Iss. 2
Open Access | Times Cited: 2
How to sensitize glioblastomas to temozolomide chemotherapy: a gap-centered view
Alila Miramova, Anton Gartner, Dmitri Ivanov
Frontiers in Cell and Developmental Biology (2024) Vol. 12
Open Access | Times Cited: 2
Unveiling the role of O(6)-methylguanine-DNA methyltransferase in cancer therapy: insights into alkylators, pharmacogenomics, and others
Lizhen Chen, Alex Wen
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
Novel strategies to overcome chemoresistance in human glioblastoma
Qing Tang, Ting Ren, Peiying Bai, et al.
Biochemical Pharmacology (2024), pp. 116588-116588
Closed Access | Times Cited: 2
Drug delivery in glioblastoma therapy: a review on nanoparticles targeting MGMT-mediated resistance
Inês David Torres, Joana A. Loureiro, Manuel A. N. Coelho, et al.
Expert Opinion on Drug Delivery (2022) Vol. 19, Iss. 11, pp. 1397-1415
Closed Access | Times Cited: 10
Uncover DNA damage and repair-related gene signature and risk score model for glioma
Yaqiu Wu, Ling Liu, Da Huang, et al.
Annals of Medicine (2023) Vol. 55, Iss. 1
Open Access | Times Cited: 6
A novel DNA damage and repair‐related gene signature to improve predictive capacity of overall survival for patients with gliomas
Xiaodong Li, Yichang Wang, Wei Wu, et al.
Journal of Cellular and Molecular Medicine (2022) Vol. 26, Iss. 13, pp. 3736-3750
Open Access | Times Cited: 9
Temozolomide hexadecyl ester targeted plga nanoparticles for drug-resistant glioblastoma therapy via intranasal administration
Siqi Wang, Yawen Yu, Aiping Wang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 9
Downregulation of BASP1 promotes temozolomide resistance in gliomas via epigenetic activation of the FBXO32/NF-κB/MGMT axis
Xinyi Liao, Ziwen Li, Haiqing Zheng, et al.
Molecular Cancer Research (2023) Vol. 21, Iss. 7, pp. 648-663
Open Access | Times Cited: 5
DNA repair pathways-targeted cyclovirobuxine inhibits castration-resistant prostate cancer growth by promoting cell apoptosis and cycle arrest
Ke Gao, Siying Zhu, Q. Shao, et al.
Translational Oncology (2023) Vol. 35, pp. 101708-101708
Open Access | Times Cited: 5
A multi-site phase I trial of Veliparib with standard radiation and temozolomide in patients with newly diagnosed glioblastoma multiforme (GBM)
Lawrence Kleinberg, Xiaobu Ye, Jeff Supko, et al.
Journal of Neuro-Oncology (2023) Vol. 165, Iss. 3, pp. 499-507
Open Access | Times Cited: 5

Scroll to top